(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.37%.
Benitec Biopharma's earnings in 2026 is -$48,884,000.On average, 8 Wall Street analysts forecast BNTC's earnings for 2026 to be -$35,041,421, with the lowest BNTC earnings forecast at -$36,023,955, and the highest BNTC earnings forecast at -$34,629,169. On average, 8 Wall Street analysts forecast BNTC's earnings for 2027 to be -$43,100,947, with the lowest BNTC earnings forecast at -$51,847,561, and the highest BNTC earnings forecast at -$36,793,492.
In 2028, BNTC is forecast to generate -$41,348,876 in earnings, with the lowest earnings forecast at -$58,581,010 and the highest earnings forecast at -$21,282,510.